NHL: Still room for more

Despite a burgeoning number of products in late stage development to treat non-Hodgkin's lymphoma (NHL), some of them presented at last week's American Society of Hematology meeting in Orlando, the disorder remains a market with significant opportunity for progress.

The reason is two-fold. First, available and late-stage antibody therapies target pan-B cell antigens, meaning that the therapies target all B cells, not just the cancerous ones. A few cells usually survive treatment, ultimately leading to clinical relapse. In addition, the antibodies cannot be used through multiple cycles